Company Description

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company.

It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.

Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury.

The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

The company was incorporated in 2012 and is headquartered in New York, New York.

Synaptogenix, Inc.

Country	United States
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Dr. Alan J. Tuchman M.D., MBA(FAAN)

Contact Details

Address: 1185 Avenue Of The Americas, 3rd Floor New York, New York 10036 United States
Phone	(973) 242-0005
Website	synaptogen.com

Stock Details

Ticker Symbol	SNPX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001571934
CUSIP Number	87167T201
ISIN Number	US87167T2015
Employer ID	46-1585656
SIC Code	2834

Key Executives

Name	Position
Dr. Alan J. Tuchman M.D., MBA(FAAN)	Chief Executive Officer and Director
Dr. Daniel L. Alkon M.D.	President, Chief Scientific Officer and Director
Robert Weinstein	Chief Financial Officer, Executive Vice President, Treasurer and Secretary

Latest SEC Filings

Date	Type	Title
Jun 21, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 4, 2024	8-K	Current Report
Apr 1, 2024	10-K	Annual Report
Feb 6, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Dec 21, 2023	8-K	Current Report
Nov 14, 2023	ARS	Filing
Nov 14, 2023	10-Q	Quarterly Report
Nov 13, 2023	DEF 14A	Other definitive proxy statements
Nov 6, 2023	8-K	Current Report

View All SEC Filings